Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
3.510
-0.510 (-12.69%)
At close: Nov 4, 2024, 4:00 PM
3.690
+0.180 (5.13%)
After-hours: Nov 4, 2024, 5:24 PM EST
CELZ Revenue
Creative Medical Technology Holdings had revenue of $8.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $17.00K, down -76.90% year-over-year. In the year 2023, Creative Medical Technology Holdings had annual revenue of $9.00K, down -89.84%.
Revenue (ttm)
$17.00K
Revenue Growth
-76.90%
P/S Ratio
n/a
Revenue / Employee
$4,250
Employees
4
Market Cap
4.70M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sunshine Biopharma | 30.48M |
Evoke Pharma | 7.53M |
Kindly MD | 3.10M |
Mangoceuticals | 866.79K |
Eterna Therapeutics | 162.00K |
CELZ News
- 3 months ago - Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Provides Corporate Update - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin - GlobeNewsWire
- 8 months ago - Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access - Business Wire
- 8 months ago - Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy - Business Wire
- 11 months ago - Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain - Accesswire
- 1 year ago - Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain - PRNewsWire
- 1 year ago - Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain - PRNewsWire